QLT Looks Beyond Ophthalmology To Treat Skin Cancer With Visudyne
This article was originally published in The Gray Sheet
Executive Summary
QLT expects to complete enrollment of its pivotal Visudyne trial for multiple basal cell carcinoma by year-end and envisions U.S. approval in 2005
You may also be interested in...
QLT PhotoTherapeutics
FDA approval of Visudyne (verteporfin for injection) to treat "wet" age-related macular degeneration in conjunction with lasers made by Coherent and Zeiss Humphrey Systems to activate the photodynamic therapy is announced April 13. Independent marketing of Coherent's Opal Photoactivator and Zeiss' Visulas 690 PDT lasers, which have only slightly different features, commenced immediately following approval. The Opal is priced in the $40,000-50,000 range and the Visulas is priced at $37,900-44,900, depending on configuration with or without a slitlamp
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.